通过二次药优化为双重疾病量身定制cariprazine
Caleb D Vogt1, Julie Sanchez2, Alessandro Bonifazi3
1Medicinal Chemistry Section, Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse - Intramural Research Program, National Institutes of Health, 333 Cassell Drive, Baltimore, MD, 21224, United States.
European journal of medicinal chemistry
|February 18, 2026
概括
新药候选药物在治疗并发性精神疾病和精神兴奋剂使用障碍方面表现有前途. 这些新型化合物提供了改善的多巴胺D3受体选择性,与cariprazine相比,可能减少副作用.
科学领域:
- 神经科学是一个神经科学.
- 心理药理学 心理药理学
- 药用化学 医学化学
背景情况:
- 卡里普拉辛治疗精神分裂症,双相情感障碍和抑郁症,通常与精神兴奋剂使用障碍并发症.
- 目前没有批准药物治疗精神兴奋剂使用障碍,这是一个重要的未满足的医疗需求.
- 多巴胺D3受体 (D3R) 是物质使用障碍的关键标.
研究的目的:
- 开发具有增强D3R选择性超过D2R的新药候选药物,用于治疗双重疾病.
- 调查D3R选择性的提高是否与卡里普拉辛相比,转化为更好的治疗特征.
主要方法:
- 通过修改二级药,合成卡里普拉类型.
- 评估了对D3R和D2R的结合亲和力和选择性.
- 作为D3R部分激动剂的评估功能活性.
- 在大鼠肝脏显微体中确定了代谢稳定性.
主要成果:
- 与卡里普拉辛 (3.6倍) 相比,类似物对D3R具有很高的亲和力 (Ki = 0.2482.97 nM) 和对D2R有更好的选择性 (5.039倍).
- 衍生品作为D3R部分激动剂,具有与cariprazine类似的脱特征.
- 领先的候选药物 (8) 显示了改善的代谢稳定性 (t1/2 ≥ 61.3 分钟).
结论:
- 开发了具有优越D3R选择性的新型卡里普拉辛类型.
- 这些候选药物有可能用于治疗并发性精神兴奋剂使用障碍,并可能减少副作用.
- 对于双重疾病治疗,需要对主要候选人 (8) 进行进一步的调查.
相关概念视频
Pharmacokinetic–Pharmacodynamic Relationship: Problems
24
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
24
Drug Therapy
316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
316
Psychosis: Goals of Pharmacotherapy
555
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
555
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
724
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
724
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
291
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
291
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K


